Home » Stocks » CGIX

Cancer Genetics, Inc. (CGIX)

Stock Price: $2.20 USD -0.04 (-1.79%)
Updated November 23, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 8.96M
Revenue (ttm) 6.33M
Net Income (ttm) -4.53M
Shares Out 4.07M
EPS (ttm) -2.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 23
Last Price $2.20
Previous Close $2.24
Change ($) -0.04
Change (%) -1.79%
Day's Open 2.27
Day's Range 2.18 - 2.27
Day's Volume 131,595
52-Week Range 1.92 - 10.39

More Stats

Market Cap 8.96M
Enterprise Value 8.01M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 4.07M
Float 3.48M
EPS (basic) -1.94
EPS (diluted) -2.07
FCF / Share -2.87
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 29,929
Short Ratio 0.25
Short % of Float 0.86%
Beta 2.87
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.42
PB Ratio 1.91
Revenue 6.33M
Operating Income -4.38M
Net Income -4.53M
Free Cash Flow -6.69M
Net Cash 953,000
Net Cash / Share 0.23
Gross Margin 56.94%
Operating Margin -69.27%
Profit Margin -71.50%
FCF Margin -105.69%
ROA -14.90%
ROE -68.71%
ROIC 271.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$90.00*
Low
90.0
Current: $2.20
High
90.0
Target: 90.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7.314.9329.1227.0518.0410.206.614.303.022.52
Revenue Growth48.11%-83.06%7.66%49.94%76.88%54.3%53.67%42.46%19.74%-
Gross Profit3.601.8411.059.953.941.751.690.37-0.10-0.99
Operating Income-5.70-7.69-18.62-16.72-21.38-19.21-8.46-7.64-8.18-6.32
Net Income-6.71-20.37-20.88-15.80-20.18-16.64-12.37-6.67-19.89-8.41
Shares Outstanding1.930.910.690.530.340.310.160.040.040.04
Earnings Per Share-3.48-22.39-30.30-30.00-58.81-54.01-109.21-316.53-468.35-201.32
Operating Cash Flow-8.66-12.55-13.56-17.85-13.60-12.34-8.08-7.58-5.07-5.73
Capital Expenditures-0.03-0.02-1.28-0.49-1.01-1.37-0.26-0.16-0.27-0.16
Free Cash Flow-8.69-12.57-14.85-18.34-14.61-13.71-8.33-7.74-5.34-5.89
Cash & Equivalents4.230.519.899.8019.7631.8549.761.072.62-
Total Debt1.662.5811.035.146.376.926.3815.1710.51-
Net Cash / Debt2.58-2.07-1.144.6713.3924.9443.38-14.10-7.89-
Assets14.9035.4152.2242.4348.8847.1155.168.957.03-
Liabilities7.5228.6025.4616.8115.8712.559.6932.9326.10-
Book Value7.396.8026.7725.6233.0234.5545.46-23.98-19.07-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cancer Genetics, Inc.
Country United States
Employees 110
CEO John A. Roberts

Stock Information

Ticker Symbol CGIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CGIX
IPO Date April 5, 2013

Description

Cancer Genetics, through its subsidiary, vivoPharm, Pty Ltd., provides contract research services primarily focusing on studies to guide drug discovery and development programs in the oncology and immuno-oncology fields. The company's clinical offerings include a portfolio of proprietary tests, such as comparative genomic hybridization microarrays and next generation sequencing panels, gene expression tests, and DNA fluorescent in situ hybridization probes targeting hematological, and human papillomavirus-associated cancers, which include cervical, anal, head, and neck cancers. It serves the biotechnology and pharmaceutical customers in the United States, Europe, and Australia. Cancer Genetics, Inc. was founded in 1999 and is headquartered in Rutherford, New Jersey.